What is the Ind-Swift Laboratories PE ratio today?
Ind-Swift Laboratories' PE ratio is 42.6 at the 29 October 2026 close (₹409.80 a share): a market capitalisation of ₹3,564 crore divided by consolidated net profit of ₹83.6 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹41.4 crore) it is 86.0.
What is the Ind-Swift Laboratories net worth?
Ind-Swift Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,474 crore on 30 September 2026, up 12.8% from ₹1,308 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹3,564 crore at the 29 October 2026 close.
What is the Ind-Swift Laboratories book value per share?
Ind-Swift Laboratories' book value per share was ₹169.54 on 30 September 2026: shareholders' equity of ₹1,474 crore divided by the 8.7 crore shares in issue, up 5.8% from ₹160.21 a year earlier. The share price at the 29 October 2026 close was ₹409.80.
What is the Ind-Swift Laboratories PB ratio (price to book value)?
Ind-Swift Laboratories' price-to-book (PB) ratio is 2.42 at the 29 October 2026 close: a market capitalisation of ₹3,564 crore divided by shareholders' equity (book value) of ₹1,474 crore on 30 September 2026. That is a book value of ₹169.54 per share against a share price of ₹409.80.
What is the Ind-Swift Laboratories ROE and ROCE?
In FY26, Ind-Swift Laboratories' return on equity (ROE) was 3.2% and its return on capital employed (ROCE) was 1.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 23.8% and ROCE −4.1%.
What is the Ind-Swift Laboratories shareholding pattern?
On 30 September 2026, Ind-Swift Laboratories' shares were held by promoters 42.93%, foreign portfolio investors (FII/FPI) 10.78%, domestic institutions (DII) 0.20% (including mutual funds at 0.00%) and retail and other non-institutional investors 46.09%. Over the year, FII holding was down 4.02 percentage points from 14.80% and DII holding was down 0.48 percentage points from 0.68%.
What is the Ind-Swift Laboratories market cap?
Ind-Swift Laboratories' market capitalisation was ₹3,564 crore at the 29 October 2026 close: 8.7 crore shares at ₹409.80 each.
Is Ind-Swift Laboratories debt free?
No. Ind-Swift Laboratories had borrowings of ₹19.6 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹385 crore, so it held net cash of ₹366 crore.
What is the Ind-Swift Laboratories EPS?
Ind-Swift Laboratories' basic earnings per share (EPS) were ₹4.95 in FY26, against ₹37.25 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹9.76.
What is the Ind-Swift Laboratories debt to equity ratio?
Ind-Swift Laboratories' debt-to-equity ratio was 0.01 on 30 September 2026: borrowings of ₹19.6 crore against total equity of ₹1,474 crore. A year earlier, on 30 September 2025, it was 0.02.
What is the Ind-Swift Laboratories promoter holding?
Promoters held 42.93% of Ind-Swift Laboratories on 30 September 2026, unchanged from the previous quarter and up 3.43 percentage points from 39.50% a year earlier, according to the shareholding pattern filed with NSE.
What is the Ind-Swift Laboratories free cash flow?
In FY26, Ind-Swift Laboratories generated ₹63.2 crore of cash from operations and spent ₹87.7 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹151 crore. In FY25 it was −₹89.9 crore.
What are the Ind-Swift Laboratories latest quarterly results?
Ind-Swift Laboratories' latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹34.2 crore, up 328.3% from ₹8 crore in Q2 FY26; revenue from operations ₹240 crore, up 57.5% year on year.
What is the Ind-Swift Laboratories revenue and profit in FY26?
In FY26 (April 2025–March 2026), Ind-Swift Laboratories' consolidated net profit was ₹41.4 crore, down 83.5% from ₹250 crore in FY25, on revenue from operations of ₹641 crore (up 14.2%). Over three years, from FY23, net profit was down 13.0%.
When are the Ind-Swift Laboratories next results?
Ind-Swift Laboratories has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Ind-Swift Laboratories compare with its peers?
On FY26 consolidated figures, against SMS Pharmaceuticals, Solara Active Pharma Sciences and Dishman Carbogen Amcis: Ind-Swift Laboratories' operating margin of 2.3% is the lowest of the four (SMS Pharmaceuticals 14.8%, Solara Active Pharma Sciences 6.4%, Dishman Carbogen Amcis 7.7%; peer average 9.6%); its return on equity of 3.2% is the second highest of the four (SMS Pharmaceuticals 14.3%, Solara Active Pharma Sciences −0.6%, Dishman Carbogen Amcis 1.6%; peer average 5.1%); its revenue growth over three years of −19.0% a year is the lowest of the four (SMS Pharmaceuticals 19.3% a year, Solara Active Pharma Sciences −1.8% a year, Dishman Carbogen Amcis 6.7% a year; peer average 8.1% a year).
Ind-Swift Laboratories vs SMS Pharmaceuticals: how do they compare?
In FY26, Ind-Swift Laboratories earned net profit of ₹41.4 crore on revenue of ₹641 crore, against ₹102 crore on ₹887 crore for SMS Pharmaceuticals. Ind-Swift Laboratories' operating margin was 2.3% (SMS Pharmaceuticals 14.8%) and its return on equity 3.2% (SMS Pharmaceuticals 14.3%). At the 29 October 2026 close, Ind-Swift Laboratories' market capitalisation was ₹3,564 crore against ₹4,550 crore for SMS Pharmaceuticals, and its PE ratio on FY26 profit 86.0 against 44.6.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
